Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The treatment of lupus nephritis (LN) remains problematic because the current treatment regimen based on unspecific immunosuppressants such as steroids, cyclophosphamide and mycophenolate has significant side effects and is often inefficient. B-cell ablation with the chimeric anti-CD20 antibody rituximab (RTX) has been considered as an alternative treatment option but the randomized controlled LUNAR trial failed to show any additive effect of RTX beyond a steroid-mycophenolate mofetil (MMF) combination for LN type III/IV/V in incident patients. At present, no such trial is available for the use of RTX in refractory LN. METHODS: We analysed existing evidence on this topic by performing a systematic analysis of reports that document outcomes of RTX treatment for refractory LN. RESULTS: Out of 233 reports, we selected 26 for analysis, which described 300 patients with a mean follow-up of 60 weeks. The complete or partial response criteria were met by 87% of patients with LN class III, 76% with class IV and 67% with class V, respectively. Mixed classes responded in 76% of patients. RTX induced complete responses in 60% (type III), 45% (type IV), 40% (type V) and 24% (mixed types), respectively. CONCLUSIONS: Our systematic review of existing evidence suggests that RTX effectively induces remission of LN in patients who have not achieved remission with standard therapies. Another randomized controlled trial should be conducted to test the efficacy of RTX in refractory LN.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited
Weening, J. J., D’Agati, V. D., Schwartz, M. M., Seshan, S. V., Alpers, C. E., Appel, G. B., Balow, J. E., Bruijn, J. A., Cook, T., Ferrario, F., et al. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000108969.21691.5d · Cited by 2,008 · cited 1×
“Classes of LN according to the ISN/RPA classification [3]”
MethodRovin, B. H., Furie, R., Latinis, K., Looney, R. J., Fervenza, F. C., Sanchez‐Guerrero, J., Maciuca, R., Zhang, D., Garg, J. P., Brunetta, P., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34359 · Cited by 1,461
Austin, H. A., Klippel, J. H., Balow, J. E., Le Riche, N. G. H., Steinberg, A. D., Plotz, P. H., & Decker, J. L. (1986) · New England Journal of Medicine · doi:10.1056/nejm198603063141004 · Cited by 1,185 · cited 2×
“One of the first RCT on LN documented that highdose steroids alone were not as effective as steroids plus cyclophosphamide (CYC) to maintain long-term renal function and flare-free intervals [4].”
BackgroundResultMycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis
Appel, G. B., Contreras, G., Dooley, M. A., Ginzler, E. M., Isenberg, D., Jayne, D., Li, L.-S., Mysler, E., Sa[Combining Acute Accent]nchez-Guerrero, J., Solomons, N., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008101028 · Cited by 1,118 · cited 1×
“Recently, mycophenolate mofetil (MMF) was proven to be as efficient as highdose CYC in controlling class III/IV/V LN in Caucasian patients [5].”
BackgroundChan, O. T. M., Hannum, L. G., Haberman, A. M., Madaio, M. P., & Shlomchik, M. J. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.10.1639 · Cited by 698 · cited 1×
“In fact, in SLE, systemic inflammation alone is unable to elicit LN in the absence of mature B-cells, lupus autoantibodies and renal immune complex deposition [8], even though mature B-cells appear to be more important than the autoantibodies themselves [9, 10].”
BackgroundAn open study of B lymphocyte depletion in systemic lupus erythematosus
Leandro, M. J., Edwards, J. C., Cambridge, G., Ehrenstein, M. R., & Isenberg, D. A. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10541 · Cited by 576 · cited 1×
“The lead compound in this area is rituximab (RTX), a chimeric anti-CD20 antibody that efficiently and reliably depletes CD20-positive B-cells [11].”
BackgroundSfikakis, P. P., Boletis, J., Lionaki, S., Vigklis, V., Fragiadaki, K., Iniotaki, A. G., & Moutsopoulos, H. Μ. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20858 · Cited by 427 · cited 1×
“[35] Prospective 10 29 6 1:9 Vigna-perez et al.”
Terrier, B., Amoura, Z., Ravaud, P., Hachulla, E., Jouenne, R., Combe, B., Bonnet, C., Cacoub, P., Cantagrel, A., De Bandt, M., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27541 · Cited by 411
Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases
Gottenberg, J.-E., Guillevin, L., Lambotte, O., Combe, B., Allanore, Y., Cantagrel, A., Larroche, C., Soubrier, M., Bouillet, L., Dougados, M., et al. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.029694 · Cited by 401 · cited 2×
“[23] Retrospective 3 28 10 2:1”
Background
Cited by
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Fanouriakis, A., Kostopoulou, M., Cheema, K., Anders, H.-J., Aringer, M., Bajema, I., Boletis, J., Frangou, E., Houssiau, F. A., Hollis, J., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-216924 · Cited by 825
Self-citationKDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS
Rovin, B. H., Ayoub, I. M., Chan, T. M., Liu, Z.-H., Mejía-Vilet, J. M., & Floege, J. (2024) · Kidney International · doi:10.1016/j.kint.2023.09.002 · Cited by 517
The Pathogenesis of Lupus Nephritis
Lech, M., & Anders, H.-J. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013010026 · Cited by 496
Self-citationYap, D. Y. H., & Chan, T. M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246231 · Cited by 192
Metadata
- Authors
- Weidenbusch, M., Römmele, C., Schröttle, A., & Anders, H.-J.
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-07-03
- Volume
- 28
- Issue
- 1
- Pages
- 106-111
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- OpenAlex
- W2111077593
- Cited by
- 190
- References
- 31
- FWCI
- 11.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.